Thymulin Research, Specifications & Scientific Information

Introduction

Thymulin is nine amino acids and one zinc ion, and the zinc is not an accessory. The peptide alone is inactive. A 1985 study found that the epitope monoclonal antibodies recognise on this molecule exists only when zinc is bound ^[1], and nuclear magnetic resonance work three years later characterised the zinc(II)–nonapeptide complexes directly ^[2]. Everything else about the compound follows from that: its assay, its behaviour in nutritional deficiency, and the reason a bare peptide sequence is an incomplete description of it.

It is also, unusually for this library, a compound with a finished history rather than an open one. Discovered in the early 1970s as facteur thymique sérique, characterised as a thymic epithelial hormone over the following decade, tested against placebo in two randomised double-blind trials reported in 1987 ^[3] — and then not pursued. No trial of the peptide is registered on ClinicalTrials.gov. Contemporary work uses gene transfer in animals rather than the peptide itself ^{[5, 8]}.

What Is Thymulin?

Thymulin is a nonapeptide hormone, pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, produced exclusively by thymic epithelial cells and coupled to a zinc ion that confers biological activity on the molecule. It was characterised as a hormone involved in intrathymic and extrathymic T-cell differentiation, and its production and secretion are strongly influenced by the neuroendocrine system ^{[5, 6]}.

The synthetic peptide has an International Nonproprietary Name, nonathymulin, and two register identities exist for the same nine residues — one for the synthetic substance and one for the circulating natural hormone, each with its own CAS number. Both are set out in the chemistry section below.

The regulatory position is simple and old. It has never been approved by the U.S. Food and Drug Administration for any indication, and no marketing application for it is on record in the United States. An INN is a naming decision by the World Health Organization; it is not an approval, and the compounds that hold one and were never approved outnumber those that were.

Thymulin Specifications

Two register entries exist for the same nonapeptide and both are correct. PubChem compound identifier 3085284, CAS registry number 63958-90-7 and UNII 9H198D04WL carry it under the International Nonproprietary Name nonathymulin — the synthetic peptide. PubChem compound identifier 71300623 with CAS registry number 78922-62-0 carries it as serum thymic factor, the circulating natural hormone. Both records give the same molecular formula C33H54N12O15 and the same average mass 858.9 g/mol, because they describe the same nine residues. Neither describes the biologically active species. Activity requires a bound zinc ion, and the zinc-free peptide is inactive, so the formula and mass above are those of the apopeptide rather than of the molecule that does the work. The N-terminal residue is pyroglutamate, a cyclised glutamine, which is a defined structural feature and not a synthesis artefact.

Values that a public register does not carry are shown as not publicly characterised rather than estimated. Identifiers are reference values; the certificate of analysis supplied with a laboratory order is the record for a given lot.

How Does Thymulin Work?

No receptor for thymulin has been identified, which places it in the same position as several other peptides in this library — but for a different reason, and with a much more specific molecular story underneath.

What is established is that the molecule's activity is a property of the zinc complex. The peptide chain provides the ligands; the zinc organises them into the conformation that carries the recognised epitope ^{[1, 2]}. This has a consequence that reaches all the way into clinical measurement. Serum thymulin activity is assayed biologically, so a low reading can mean less peptide, less available zinc, or both — and in mild zinc deficiency it means the second. In human subjects made mildly zinc-deficient by diet, and in mildly deficient sickle cell anaemia subjects, serum thymulin activity fell and was corrected by zinc supplementation given either to the subject or to the sample ^[4].

The functional account above that level is T-cell differentiation: the hormone acts on intrathymic and extrathymic maturation of T lymphocytes, and the zinc-deficiency work reported parallel changes in lymphocyte subpopulations — a decreased T4/T8 ratio and reduced interleukin-2 activity during depletion, both corrected by repletion ^[4].

A second strand of the biology is directional the other way round: the thymus as an endocrine organ that signals to the hypothalamus and pituitary. Thymulin has been described as a hypophysotropic peptide, and gonadotropin-releasing activity attributed to it changes with age ^{[5, 7]}.

Thymulin Mechanism of Action

In vitro research

The zinc-dependent epitope. Monoclonal antibodies raised against the molecule recognise an epitope that is present only when zinc is bound, establishing that the metal is part of the biologically relevant structure rather than a stabiliser of it ^[1].

Structural characterisation of the complexes. Nuclear magnetic resonance study of the lymphocyte-differentiating thymic factor examined the zinc(II)–nonapeptide complexes and described how the metal is coordinated by the peptide ^[2]. Few short peptides in this field have structural work of this kind behind them.

Zinc restores activity in vitro. Serum from mildly zinc-deficient human subjects regained thymulin activity when zinc was added to the sample directly, as well as when the subject was supplemented ^[4]. An effect that is reversible in the test tube is strong evidence that the deficiency lies in the complex and not in peptide synthesis.

Thymocyte second messengers. Early work examined cyclic nucleotide and prostaglandin E2 responses in peanut-agglutinin-fractionated thymocytes, which is the level at which the hormone's action on differentiating cells was originally probed ^[6].

Findings in this section were obtained in cell-free systems, in serum samples and in fractionated thymocytes. Nothing in them establishes anything about intact animals or about humans, except where a human sample was the material — and there the finding is about the assay, not about administering the compound.

What Is Thymulin Being Researched For?

• Thymic endocrinology and T-cell differentiation — the original and still the central subject ^{[5, 6]}.
• Serum thymulin activity as an index of zinc status — a use of the hormone as a measurement rather than as an intervention, and the most robust part of its human literature ^[4].
• The thymus–neuroendocrine axis — including hypophysotropic activity and age-related change in gonadotropin-releasing activity ^{[7, 5]}.
• Anti-inflammatory and analgesic activity in rodent brain, and the gene-transfer approaches that grew out of it ^{[5, 8]}.
• Rheumatoid arthritis — historically, in the 1987 randomised trials, with no subsequent programme ^[3].

None of that research is research into, or evidence about, research-grade material supplied for laboratory use.

Human Research on Thymulin

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Rheumatoid arthritis, two randomised trials, 1987

Design. Two randomised, double-blind, placebo-controlled trials of the synthetic peptide, reported together, comparing three daily amounts — 1 mg, 5 mg and 10 mg — against placebo ^[3].

Result as reported. The 5 mg arm was the most effective of the three. Global assessment across all participants who entered the trials showed significant clinical improvement, 56% against 17% on placebo (p < 0.02), supported by four objective parameters. Adverse effects were described as minimal ^[3].

The finding that complicates it. The clinical effect was not accompanied by clear changes in immunological parameters — in a compound whose entire rationale is T-cell differentiation. The authors did report a significant correlation between clinical response and T-cell subset imbalance assessed by monoclonal antibodies and a functional suppressor T-cell assay ^[3]. A treatment effect without the mechanistic change it predicts is a result that needs explaining, and it was not explained.

Limitations. Two trials from the 1980s, reported jointly, with participant numbers, randomisation method and allocation concealment not stated in the indexed record. A global assessment as the headline outcome is a subjective measure even under blinding. And the strongest evidence that the field did not find the result decisive is what followed: no phase 3 programme, no registration, and no registered trial of the compound since.

Serum thymulin in zinc deficiency, 1988

Design. Serum thymulin activity measured in three models of mild human zinc deficiency: two volunteers in whom deficiency was induced by diet, mildly deficient adults with sickle cell anaemia, and a further deficient group, with diagnosis based on zinc assayed in lymphocytes, granulocytes and platelets ^[4].

Result. Serum thymulin activity fell with mild zinc deficiency and was corrected both by supplementing the subject and by adding zinc to the sample. During the depletion phase the experimental model showed increased T101-negative, surface-immunoglobulin-negative cells, a decreased T4/T8 ratio and reduced interleukin-2 activity, all corrected on repletion. Comparable changes appeared in the mildly deficient sickle cell subjects ^[4].

What this study is and is not. It is a careful human study establishing that measured thymulin activity is a sensitive index of zinc status, and it links zinc status to T-cell function through a plausible route. It is not a study of administering thymulin, and nothing in it supports a claim about giving the peptide to anyone.

Preclinical Research on Thymulin

Animal research

Contemporary animal work has largely moved from administering the peptide to expressing it.

Gene transfer in allergic asthma. DNA nanoparticle-mediated thymulin gene transfer was reported to prevent airway remodelling in an experimental allergic asthma model ^[8].

Central anti-inflammatory and analgesic activity. A review of this field describes anti-inflammatory and analgesic properties reported for thymulin in the brain, and records an observation that prompted much of the gene-transfer work: an adenoviral vector carrying a synthetic thymulin gene, injected stereotaxically into rat brain, achieved much longer expression than adenovirally mediated expression of other genes in the same setting — which the authors read as the peptide's anti-inflammatory activity protecting transduced cells from immune clearance ^[5].

Endocrine consequences of thymic deficiency. Gene-transfer approaches have also been examined for preventing endocrine and metabolic alterations that appear in thymus-deficient animal models, and gonadotropin-releasing activity attributed to the hormone has been studied across age ^{[5, 7]}.

Two limits apply throughout. Gene transfer produces sustained local expression of a peptide, which is not the same intervention as administering that peptide, and results from one cannot be read as results for the other. And these are rodent studies: findings described in this section were observed in animals, and nothing in them establishes anything about humans.

Current Research Status

Status as of September 22, 2026. This block is rendered from maintained fields, not from prose, so it cannot go stale in one place and stay current in another.

Thymulin vs Related Compounds

Against Thymosin alpha-1

Thymosin alpha-1 is a 28-residue thymic peptide with an approval history in several countries and a far larger modern clinical literature. Both are described as thymic peptides acting on T-cell function; they are different molecules, from different fractions, with different evidence bases and different regulatory positions.

Against Thymalin

Thymalin is a polypeptide complex extracted from thymus tissue, not a defined molecule. Thymulin has a sequence, a mass, register entries and a structurally characterised metal complex. The two are not comparable as substances, whatever their shared tissue of origin.

The zinc question

No other peptide in this library has an absolute metal requirement of this kind. It means that material supplied as the bare nonapeptide is, by the standard the founding literature set, not the active species ^{[1, 2]} — a distinction that has no parallel among the other compounds here.

Against host-defence peptides

LL-37 is grouped with this compound only by field — immune peptides — and shares no target, structure or mechanism with it.

No comparison of effect between these compounds is made on this page.

Chemical & Molecular Characteristics

Thymulin is nine residues with a cyclised N-terminus and no cysteine, no aromatic residue and one basic side chain. Four features matter analytically.

Two register entries describe the same peptide. PubChem compound identifier 3085284, CAS registry number 63958-90-7 and UNII 9H198D04WL carry the synthetic substance under the INN nonathymulin. PubChem compound identifier 71300623 with CAS registry number 78922-62-0 carries the natural circulating hormone as serum thymic factor. Both give molecular formula C33H54N12O15 and average mass 858.9 g/mol, because the nine residues are the same. Neither duplication is an error; recognising which record a source is quoting is simply part of reading this literature.

Neither record includes the zinc. The formula and mass above are those of the apopeptide. The species with biological activity is the zinc complex ^[1], and no ordinary specification field on a certificate of analysis expresses that. A mass-spectrometric confirmation of 858.9 daltons confirms the peptide and says nothing about whether the material can do what thymulin does.

The N-terminal pyroglutamate is a defined feature, not an artefact. Glutamine at a peptide's N-terminus cyclises readily to pyroglutamate, and in many peptides this is an unwanted degradation product that shifts the mass by minus 17 daltons. Here the cyclised form is the correct structure. The analytical consequence runs the other way: a preparation containing the uncyclised nonapeptide contains a related substance, not the hormone.

No aromatic residue, so no ultraviolet handle. There is no tryptophan, tyrosine or phenylalanine, so absorbance at 280 nm is negligible and quantification depends on peptide-bond absorbance near 214 nm or on an alternative method. An enzyme immunoassay for the synthetic peptide was developed for exactly this kind of reason.

Two serines and an asparagine bring known liabilities. Asparagine deamidates to aspartate with a mass shift of plus one dalton, which is at the edge of what routine methods resolve, and serine residues are sites for the O-linked acyl chemistry that complicates short-peptide synthesis. Neither is exotic; both mean that a mass measurement alone is weak evidence of identity for this molecule.

Frequently Asked Questions

Scientific References

1. Dardenne M, Savino W, Berrih S, et al.. A zinc-dependent epitope on the molecule of thymulin, a thymic hormone Proceedings of the National Academy of Sciences of the United States of America; 1985. PMID 2413455 doi:10.1073/pnas.82.20.7035
2. Cung MT, Marraud M, Lefrancier P, et al.. NMR study of a lymphocyte differentiating thymic factor. An investigation of the Zn(II)-nonapeptide complexes (thymulin) The Journal of biological chemistry; 1988. PMID 3356698
3. Amor B, Dougados M, Mery C, et al.. Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials Annals of the rheumatic diseases; 1987. PMID 3310925 doi:10.1136/ard.46.7.549
4. Prasad AS, Meftah S, Abdallah J, et al.. Serum thymulin in human zinc deficiency The Journal of clinical investigation; 1988. PMID 3262625 doi:10.1172/JCI113717
5. Reggiani PC, Morel GR, Cónsole GM, et al.. The thymus-neuroendocrine axis: physiology, molecular biology, and therapeutic potential of the thymic peptide thymulin Annals of the New York Academy of Sciences; 2009. PMID 19236333
6. Goya RG, Brown OA, Pléau JM, et al.. Thymulin and the neuroendocrine system Peptides; 2004. PMID 15003367 doi:10.1016/j.peptides.2003.11.002
7. Brown OA, Sosa YE, Dardenne M, et al.. Studies on the gonadotropin-releasing activity of thymulin: changes with age The journals of gerontology. Series A, Biological sciences and medical sciences; 2000. PMID 10811143 doi:10.1093/gerona/55.4.b170
8. da Silva AL, Martini SV, Abreu SC, et al.. DNA nanoparticle-mediated thymulin gene therapy prevents airway remodeling in experimental allergic asthma Journal of controlled release : official journal of the Controlled Release Society; 2014. PMID 24556417 doi:10.1016/j.jconrel.2014.02.010

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.